{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071974","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.510442+00:00","generated_at":"2026-05-16T00:03:53.957134+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved","bullets":["Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).","Royalty revenue from GSK $250.3M; IST U.S. net product sales $119.2M (+47% YoY).","FDA approved NUZOLVENCE (zoliflodacin) for uncomplicated gonorrhea in Dec 2025.","Guidance: IST U.S. net product sales at least $150M in 2026.","$125M repurchase program initiated; 797,298 shares repurchased for $16.0M as of year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071974","json":"https://secwatch.observer/filing/0001193125-26-071974.json","markdown":"https://secwatch.observer/filing/0001193125-26-071974.md","text":"https://secwatch.observer/filing/0001193125-26-071974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/0001193125-26-071974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000119312526071974/d23292d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:03:53.957134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}